Kooperativer Bibliotheksverbund

In: International Journal of Developmental Neuroscience, Wiley, Vol. 29, No. 4 ( 2011-06), p. 475-481

Abstract: Recently, superior cervical ganglionectomy has been performed to investigate a variety of scientific topics from regulation of intraocular pressure to suppression of lingual tumour growth. Despite these recent advances in our understanding of the functional mechanisms underlying superior cervical ganglion (SCG) growth and development after surgical ablation, there still exists a need for information concerning the quantitative nature of the relationships between the removed SCG and its remaining contralateral ganglion and between the remaining SCG and its modified innervation territory. To this end, using design‐based stereological methods, we have investigated the structural changes induced by unilateral ganglionectomy in sheep at three distinct timepoints (2, 7 and 12 weeks) after surgery. The effects of time, and lateral (left‐right) differences, were examined by two‐way analyses of variance and paired t ‐tests. Following removal of the left SCG, the main findings were: (i) the remaining right SCG was bigger at shorter survival times, i.e. 74% at 2 weeks, 55% at 7 weeks and no increase by 12 weeks, (ii) by 7 weeks after surgery, the right SCG contained fewer neurons (no decrease at 2 weeks, 6% fewer by 7 weeks and 17% fewer by 12 weeks) and (iii) by 7 weeks, right SCG neurons were also larger and the magnitude of this increase grew substantially with time (no rise at 2 weeks, 77% by 7 weeks and 215% by 12 weeks). Interaction effects between time and ganglionectomy‐induced changes were significant for SCG volume and mean perikaryal volume. These findings show that unilateral superior cervical ganglionectomy has profound effects on the contralateral ganglion. For future investigations, it would be interesting to examine the interaction between SCGs and their innervation targets after ganglionectomy. Is the ganglionectomy‐induced imbalance between the sizes of innervation territories the milieu in which morphoquantitative changes, particularly changes in perikaryal volume and neuron number, occur? Mechanistically, how would those changes arise? Are there any grounds for believing in a ganglionectomy‐triggered SCG cross‐innervation and neuroplasticity?

Type of Medium: Online Resource

ISSN: 0736-5748 , 1873-474X

URL: Article

DOI: 10.1016/j.ijdevneu.2011.02.002

Language: English

Publisher: Wiley

Publication Date: 2011

detail.hit.zdb_id: 2012538-0

detail.hit.zdb_id: 2013748-5

SSG: 12

In: Pesquisa Veterinária Brasileira, FapUNIFESP (SciELO), Vol. 28, No. 6 ( 2008-06), p. 279-284

Abstract: Aural plaque is a variant of equine papillomatosis. Clinical examination was performed on 306 Mangalarga and 275 Quarter Horses to compare the occurrence of aural plaques among animals and to characterize clinical and histological findings for the disease. Aural plaques occurred in 57% of Mangalarga and in 35% of Quarter breeds. Clinically the lesions consisted of flat, desquamated and hypochromic plaques formed by coalescence of small papules. The main histopathological findings were epidermal hyperplasia and hypomelanosis with abrupt change between the normal and the affected epithelium.

Type of Medium: Online Resource

ISSN: 0100-736X

URL: Article

DOI: 10.1590/S0100-736X2008000600004

Language: Unknown

Publisher: FapUNIFESP (SciELO)

Publication Date: 2008

In: Autophagy, Informa UK Limited, Vol. 8, No. 4 ( 2012-04), p. 445-544

Type of Medium: Online Resource

ISSN: 1554-8627 , 1554-8635

URL: Article

DOI: 10.4161/auto.19496

Language: English

Publisher: Informa UK Limited

Publication Date: 2012

detail.hit.zdb_id: 2262043-6

SSG: 12

In: Frontiers in Veterinary Science, Frontiers Media SA, Vol. 8 ( 2021-6-9)

Abstract: The aim of this study was to estimate the energy and protein requirements for maintenance and growth of lambs. A total of 35 crossbreed Dorper × Santa Ines lambs [31 ± 1.28 kg of initial body weight (BW) and 4 months old] were distributed in a completely randomized design with three treatments groups ( ad libitum , 30 and 60% of feed restriction). Five lambs were slaughtered at the beginning of the experimental trial as a reference group to estimate the initial empty BW (EBW) and body composition. When the animals of the ad libitum treatment reached a BW average of 47.2 kg, at day 84 of trial, all lambs were slaughtered. The feed restriction promoted reduction in body fat ( P & lt; 0.001) and energy concentration ( P & lt; 0.001), while protein showed a quadratic response ( P = 0.05). The equations obtained for NEg and NPg requirements were 0.2984 × EBW 0.75 × EBWG 0.8069 and 248.617 × EBW −0.15546 , respectively. The net energy (NEm) and protein (NPm) for maintenance were 71.00 kcal/kg EBW 0.75 /day and 1.76 g/kg EBW 0.75 /day, respectively. In conclusion, the NEg and NPg requirement for lambs with 30 kg of BW and 200 g of average daily gain (ADG) were 0.736 Mcal/day and 24.38 g/day, respectively. Our findings indicate that the NEm for crossbreed Dorper × Santa Ines lambs is similar to those recommended by the international committees; however, we support the hypothesis that the requirements for gain are lower.

Type of Medium: Online Resource

ISSN: 2297-1769

URL: Article

DOI: 10.3389/fvets.2021.676956

Language: Unknown

Publisher: Frontiers Media SA

Publication Date: 2021

detail.hit.zdb_id: 2834243-4

In: IEEE Access, Institute of Electrical and Electronics Engineers (IEEE), Vol. 12 ( 2024), p. 139865-139882

Type of Medium: Online Resource

ISSN: 2169-3536

URL: Article

DOI: 10.1109/ACCESS.2024.3462436

Language: Unknown

Publisher: Institute of Electrical and Electronics Engineers (IEEE)

Publication Date: 2024

detail.hit.zdb_id: 2687964-5

In: Blood, American Society of Hematology, Vol. 138, No. Supplement 1 ( 2021-11-05), p. 3134-3134

Abstract: Introduction: NKTR-255, an investigational novel polymer-conjugated recombinant human interleukin (IL)-15 agonist, maintains the full spectrum of IL-15 biology and provides sustained pharmacodynamic (PD) responses without the need for daily dosing. NKTR-255 engages IL-15Rα and IL-2/IL-15Rβγ leading to natural killer (NK) and CD8 + T-cell expansion, proliferation, and activation. In preclinical studies, NKTR-255 enhanced antibody-dependent cellular cytotoxicity (ADCC) of each of daratumumab, rituximab, trastuzumab, and cetuximab, resulting in synergistic anticancer activity. This ongoing Phase 1 trial (NCT04136756) evaluates the safety, tolerability, and pharmacokinetic (PK)/PD of NKTR-255 in patients with hematologic malignancies, including determination of the recommended Phase 2 dose (RP2D). Methods: Heavily pretreated patients with relapsed/refractory multiple myeloma (MM) or non-Hodgkin lymphoma (NHL) received escalating doses of NKTR-255 intravenously every 3 weeks. Patients were observed following the first NKTR-255 dose for dose-limiting toxicity. Preliminary PK and PD analyses were conducted. NKTR-255-mediated activation of the immune system was assessed by flow cytometry and plasma cytokine analysis. Fold change was calculated as treatment with NKTR-255 over baseline (baseline = 1). Results: As of June 8, 2021, 14 patients were enrolled, ranging in age from 49 to 80 years; 71% male. Eight (57%) had MM and 6 (43%) had NHL. Two (25%) of 8 patients with MM and 2 (33%) of 6 patients with NHL had received prior chimeric antigen receptor T-cell (CAR-T) therapy. The 14 patients were dosed at 4 levels: (1.5 µg/kg: 3 patients; 3.0 µg/kg: 4 patients; 4.5 µg/kg: 4 patients; 6.0 µg/kg: 3 patients). Among the 11 response-evaluable patients, 7 patients (64%) reported disease stabilization (4/5 [80%] MM patients; 3/6 [50%] NHL patients). Treatment-related adverse events occurring in ≥30% of patients were pyrexia (12/14; 86%), chills (10/14; 71%), nausea (8/14; 57%), headache (6/14; 43%), infusion-related reaction (5/14; 36%), and fatigue (5/14; 36%). Most adverse events were transient and resolved spontaneously, or by using standard treatment protocols. No dose-limiting toxicities were observed, and no patients discontinued NKTR-255 due to adverse events. NKTR-255- induced dose dependent, transient changes in inflammatory cytokines, including interferon-γ, monocyte chemoattractant protein-1 and IL-6 peaked at 3 to 6 hours post-infusion and resolved to baseline levels by 24 to 48 hours, supporting the safety profile of NKTR-255. Preliminary PK analyses showed target mediate disposition at the lowest dose level (1.5 µg/kg) and linear PK toward higher dose levels ( & gt;3.0 µg/kg). The average half-life of NKTR-255 was ~39 hours. No accumulation was observed following repeat dosing. There was a dose-dependent expansion in cell numbers of NK and CD8+ T cells in the peripheral blood of patients, with peak fold-changes of ~8-fold and ~2-fold respectively, within the first 2 cycles of NKTR-255 treatment at the 6.0 µg/kg dose. Consistent with NKTR-255 mechanism of action, minimal induction of Tregs was observed at all dose levels tested. Moreover, NK and CD8 + T cells demonstrated proliferative ability, which was maintained across multiple treatment cycles at all dose levels. Conclusions: In this heavily pretreated relapsed/refractory patient population with hematologic malignancies, NKTR-255 was biologically active, and demonstrated sustained increases in NK and CD8 + T cells. NKTR-255 was well tolerated with minimal treatment-related toxicities and transient upregulation and rapid decline of cytokines to baseline levels. RP2D for NKTR-255 monotherapy has not yet been reached; and dose escalation is ongoing at 9.0 µg/kg. NKTR-255 is currently being evaluated in multiple clinical studies in both hematologic malignancies and solid tumors as a monotherapy and in combination with agents that induce ADCC. Ethics approval: The study was approved by the institutional review board of each participating site. Trial registration: ClinicalTrials.gov NCT04136756 Disclosures Shah: Sanofi: Consultancy; Precision Biosciences: Research Funding; Nektar: Research Funding; Karyopharm: Consultancy; Indapta Therapeutics: Consultancy; CareDx: Consultancy; Kite: Consultancy; BMS/Celgene: Research Funding; Bluebird Bio: Research Funding; Amgen: Consultancy; CSL Behring: Consultancy; GSK: Consultancy; Janssen: Research Funding; Oncopeptides: Consultancy; Sutro Biopharma: Research Funding; Poseida: Research Funding; Teneobio: Research Funding. Budde: Merck, Inc: Research Funding; Amgen: Research Funding; Astra Zeneca: Research Funding; Mustang Bio: Research Funding; Novartis: Consultancy; Gilead: Consultancy; Roche: Consultancy; Beigene: Consultancy. Hofmeister: Sanofi: Other: National PI for CST; PI or co-PI IST; BMS/Celgene: Other: National PI for CST; PI or co-PI IST; Local PI of CST; Nektar Therapeutics: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Oncolytics: Other: National PI for CST; PI or co-PI IST; Takeda: Other: Local PI of CST; Genzyme: Membership on an entity's Board of Directors or advisory committees; Myeloma360: Membership on an entity's Board of Directors or advisory committees; Imbrium: Membership on an entity's Board of Directors or advisory committees; BioAscend: Other: CME speaker; Philips Gilmore: Other: CME speaker; Non-pharma speaker for education, research, marketing; BMS: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Amgen: Other: Non-CME speaker; BlueBird Bio: Other: Non-CME speaker; Aptitude Health: Other: Non-pharma speaker for education, research, marketing; Verascity: Other: Non-pharma speaker for education, research, marketing; TRM Oncology: Other: Non-pharma speaker for education, research, marketing; DAVA Oncology: Other: Non-pharma speaker for education, research, marketing; Medscape: Other: Non-pharma speaker for education, research, marketing; Ohio State University: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Other: IP rights, Patents & Royalties. Cowan: Bristol Myers Squibb: Research Funding; GSK: Consultancy; Abbvie: Consultancy, Research Funding; Janssen: Consultancy, Research Funding; Cellectar: Consultancy; Harpoon: Research Funding; Secura Bio: Consultancy; Nektar: Research Funding; Sanofi Aventis: Consultancy, Research Funding. Perales: Bristol-Myers Squibb: Honoraria; Celgene: Honoraria; Cidara: Honoraria; Equilium: Honoraria; Incyte: Honoraria, Other; Karyopharm: Honoraria; Kite/Gilead: Honoraria, Other; Medigene: Honoraria; Merck: Honoraria; Miltenyi Biotec: Honoraria, Other; MorphoSys: Honoraria; Nektar Therapeutics: Honoraria, Other; NexImmune: Honoraria; Novartis: Honoraria, Other; Omeros: Honoraria; Sellas Life Sciences: Honoraria; Servier: Honoraria; Takeda: Honoraria. Choi: Janssen Biotech: Speakers Bureau. Saeed: MorphoSys AG: Consultancy, Membership on an entity's Board of Directors or advisory committees; Nektar Therapeutics: Consultancy, Other: research investigator; Other-TG therapeutics: Consultancy, Other: investigator; Kite Pharma: Consultancy, Other: investigator; MEI Pharma Inc: Consultancy, Other: investigator; Celgene Corporation: Consultancy, Other: investigator; Janssen Pharmaceutica Products, LP: Consultancy, Other: investigator; sano-aventis U.S.: Consultancy, Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb Company: Consultancy; Other-Epizyme, Inc.: Consultancy; Other-Secura Bio, Inc.: Consultancy; Seattle Genetics, Inc.: Consultancy, Membership on an entity's Board of Directors or advisory committees. Chavez: AbbVie: Consultancy; Adaptive: Research Funding; ADC Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; AstraZeneca: Research Funding; BeiGene: Speakers Bureau; Bristol Myers Squibb: Speakers Bureau; Epizyme: Speakers Bureau; Karyopharm: Consultancy; Kite/Gilead: Consultancy; Merck: Research Funding; MorphoSys: Speakers Bureau; Novartis: Consultancy. Ye: Alexion, AstraZeneca Rare Disease: Other: Study investigator. Cairo: Jazz Pharmaceutical: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Amgen: Speakers Bureau; Sanofi: Speakers Bureau; Servier: Speakers Bureau; Sobi: Speakers Bureau; Omeros: Membership on an entity's Board of Directors or advisory committees; Nektar: Membership on an entity's Board of Directors or advisory committees. Rizzieri: Celltron/Teva: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: presentation to FDA for biosimilar review ; Mustang: Consultancy, Honoraria; Bayer: Consultancy, Honoraria; Stemline Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Jazz: Other: personal fee; Gilead: Other: personal fee; Incyte: Other: personal fee; Amgen: Other: personal fee; Kite: Other: personal fee; AROG: Other; Pharmacyclics: Other. Lee: Nektar Therapeutics: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Dixit: Nektar Therapeutics: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Nieves: Nektar Therapeutics: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Zhao: Nektar Therapeutics: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Wang: Nektar Therapeutics: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Kai: Nektar Therapeutics: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Marcondes: Nektar Therapeutics: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Tagliaferri: Nektar Therapeutics: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Zalevsky: Nektar Therapeutics: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company. Patel: Pfizer: Consultancy; Janssen: Consultancy, Research Funding; BMS Celgene: Consultancy, Research Funding; Oncopeptides: Consultancy.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2021-147758

Language: English

Publisher: American Society of Hematology

Publication Date: 2021

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Arquivos Brasileiros de Cardiologia, Sociedade Brasileira de Cardiologia

Type of Medium: Online Resource

ISSN: 0066-782X

URL: Article

DOI: 10.5935/abc.20170032

Language: English

Publisher: Sociedade Brasileira de Cardiologia

Publication Date: 2017

In: PLOS ONE, Public Library of Science (PLoS), Vol. 14, No. 9 ( 2019-9-16), p. e0221651-

Type of Medium: Online Resource

ISSN: 1932-6203

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

URL: Article

DOI: 10.1371/journal.pone.0221651

DOI: 10.1371/journal.pone.0221651.g001

DOI: 10.1371/journal.pone.0221651.g002

DOI: 10.1371/journal.pone.0221651.g003

DOI: 10.1371/journal.pone.0221651.g004

DOI: 10.1371/journal.pone.0221651.g005

DOI: 10.1371/journal.pone.0221651.t001

DOI: 10.1371/journal.pone.0221651.t002

DOI: 10.1371/journal.pone.0221651.t003

DOI: 10.1371/journal.pone.0221651.t004

DOI: 10.1371/journal.pone.0221651.t005

DOI: 10.1371/journal.pone.0221651.t006

DOI: 10.1371/journal.pone.0221651.s001

DOI: 10.1371/journal.pone.0221651.s002

DOI: 10.1371/journal.pone.0221651.s003

Language: English

Publisher: Public Library of Science (PLoS)

Publication Date: 2019

detail.hit.zdb_id: 2267670-3